P
Prafull Ghatage
Researcher at University of Calgary
Publications - 122
Citations - 5783
Prafull Ghatage is an academic researcher from University of Calgary. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 31, co-authored 104 publications receiving 4171 citations. Previous affiliations of Prafull Ghatage include University of Toronto & Tom Baker Cancer Centre.
Papers
More filters
Journal ArticleDOI
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman,Amit M. Oza,Domenica Lorusso,Carol Aghajanian,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Johanne I Weberpals,Andrew R Clamp,Giovanni Scambia,Alexandra Leary,Robert W Holloway,Margarita Amenedo Gancedo,Peter C.C. Fong,Jeffrey C. Goh,David M. O'Malley,Deborah K. Armstrong,Jesus Garcia-Donas,Elizabeth M. Swisher,Anne Floquet,Gottfried E. Konecny,Iain A. McNeish,Clare L. Scott,Terri Cameron,Lara Maloney,Jeff Isaacson,Sandra Goble,Caroline Grace,Thomas Harding,Mitch Raponi,James Sun,Kevin K. Lin,Heidi Giordano,Jonathan A. Ledermann,Martin Buck,A Dean,Michael Friedlander,J C Goh,Paul R. Harnett,G Kichenadasse,C L Scott,H Denys,Luc Dirix,Ignace Vergote,Laurie Elit,Prafull Ghatage,Amit M. Oza,Marie Plante,Diane Provencher,J I Weberpals,Stephen Welch,A Floquet,Laurence Gladieff,Florence Joly,A Leary,Alain Lortholary,Jean-Pierre Lotz,J. Medioni,Olivier Tredan,Benoit You,A El-Balat,C Hänle,P Krabisch,T Neunhöffer,M Pölcher,Pauline Wimberger,Amnon Amit,S Kovel,M Leviov,Tamar Safra,Ronnie Shapira-Frommer,Salomon M. Stemmer,Alessandra Bologna,N Colombo,Domenica Lorusso,Sandro Pignata,Roberto Sabbatini,G Scambia,Stefano Tamberi,Claudio Zamagni,P C Fong,A O'Donnell,M Amenedo Gancedo,A Casado Herraez,J Garcia-Donas,E M Guerra,A Oaknin,I Palacio,Iris L. Romero,A Sanchez,Susana Banerjee,A Clamp,Y Drew,Hani Gabra,D Jackson,Jonathan A. Ledermann,I A McNeish,Christine Parkinson,Melanie E Powell,C Aghajanian,D K Armstrong,Michael J. Birrer,Mary K. Buss,Setsuko K. Chambers,L-m Chen,Robert L. Coleman,R W Holloway,G E Konecny,L Ma,Mark A. Morgan,R T Morris,David G. Mutch,D M O'Malley,B M Slomovitz,E M Swisher,T Vanderkwaak,M Vulfovich +116 more
TL;DR: This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
Journal ArticleDOI
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
Stephanie M. de Boer,Melanie E Powell,Linda Mileshkin,Dionyssios Katsaros,Paul Bessette,Christine Haie-Meder,Petronella B. Ottevanger,Jonathan A. Ledermann,Pearly Khaw,Alessandro Colombo,Anthony Fyles,Marie Helene Baron,Ina M. Jürgenliemk-Schulz,Henry C Kitchener,Hans W. Nijman,G. Wilson,Susan Brooks,Silvestro Carinelli,Diane Provencher,Chantal Hanzen,Ludy C.H.W. Lutgens,Vincent T.H.B.M. Smit,Naveena Singh,V. Do,Romerai D'Amico,Remi A. Nout,Amanda Feeney,Karen W Verhoeven-Adema,Hein Putter,Carien L. Creutzberg,Mary McCormack,Karen Whitmarsh,Rozenn Allerton,Deborah Gregory,P. Symonds,Peter Hoskin,Madhavi Adusumalli,Anjana Anand,Robert Wade,Alexandra J. Stewart,Wendy Taylor,Roy F.P.M. Kruitwagen,Harry Hollema,Elizabeth Pras,An Snyers,Lukas J.A. Stalpers,Jan J. Jobsen,Annerie Slot,Jan Willem M. Mens,Tanja C. Stam,Baukelien Van Triest,Elzbieta M. Van der Steen Banasik,Karin A.J. De Winter,Michael A. Quinn,Ilka Kolodziej,Jan Pyman,Carol Johnson,Anne Capp,Roldano Fossati,Sergio Gribaudo,Andrea Lissoni,Annamaria Ferrero,Grazia Artioli,Cathy Davidson,C. Meg McLachlin,Prafull Ghatage,Paula V.C. Rittenberg,Luis Souhami,Gillian Thomas,Pierre Duvillard,Dominique Berton-Rigaud,Nicole Tubiana-Mathieu +71 more
TL;DR: Adjuvant chemotherapy given during and after radiotherapy for high-risk endometrial cancer did not improve 5-year overall survival, although it did increase failure-free survival.
Journal ArticleDOI
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
Bradley J. Monk,Thomas J. Herzog,Stanley B. Kaye,Carolyn N. Krasner,Jan B. Vermorken,Franco M. Muggia,Eric Pujade-Lauraine,Alla Lisyanskaya,A. Makhson,Janusz Rolski,Vera Gorbounova,Prafull Ghatage,Mariusz Bidziński,Keng Shen,Hextan Y.S. Ngan,Ignace Vergote,Joo-Hyun Nam,Youn C. Park,Claudia Lebedinsky,Andres Poveda +19 more
TL;DR: When combined with PLD, trabectedin improves PFS and ORR over PLD alone with acceptable tolerance in the second-line treatment of recurrent ovarian cancer.
Journal ArticleDOI
Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group
Amit M. Oza,Laurie Elit,Ming-Sound Tsao,Suzanne Kamel-Reid,J. Biagi,Diane Provencher,Walter H. Gotlieb,Paul Hoskins,Prafull Ghatage,Katia Tonkin,Helen Mackay,John Mazurka,Joana Sederias,Percy Ivy,Janet Dancey,Elizabeth Eisenhauer +15 more
TL;DR: Temsirolimus, an ester derivative of rapamycin that inhibits mTOR, was evaluated in this setting as discussed by the authors, and the single-agent activity of temsirolinus in women with recurrent or metastatic chemotherapy-naive or chemotherapy-treated endometrial cancer was evaluated.
Journal ArticleDOI
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
Stephanie M. de Boer,Melanie E Powell,Linda Mileshkin,Dionyssios Katsaros,Paul Bessette,Christine Haie-Meder,Petronella B. Ottevanger,Jonathan A. Ledermann,Pearly Khaw,Romerai D'Amico,Anthony Fyles,Marie-Helene Baron,Ina M. Jürgenliemk-Schulz,Henry C Kitchener,Hans W. Nijman,G. Wilson,Susan Brooks,Sergio Gribaudo,Diane Provencher,Chantal Hanzen,Roy F.P.M. Kruitwagen,Vincent T.H.B.M. Smit,Naveena Singh,V. Do,Andrea Lissoni,Remi A. Nout,Amanda Feeney,Karen W Verhoeven-Adema,Hein Putter,Carien L. Creutzberg,M McCormack,K Whitmarsh,R Allerton,Deborah Gregory,P. Symonds,Peter Hoskin,M Adusumalli,Anjana Anand,R Wade,Alexandra J. Stewart,W Taylor,L.C.H.W. Lutgens,Harmen Hollema,Elisabeth Pras,An Snyers,GH Westerveld,J.J. Jobsen,Annerie Slot,J.W.M. Mens,Tanja C. Stam,B. van Triest,E. Van der Steen-Banasik,Kaj De Winter,Michael A. Quinn,Ilka Kolodziej,Jan Pyman,Colin D. Johnson,Anne Capp,Roldano Fossati,Alessandro Colombo,Silvestro Carinelli,Annamaria Ferrero,G Artioli,C Davidson,C M McLachlin,Prafull Ghatage,Pvc Rittenberg,Luis Souhami,Gillian Thomas,Pierre Duvillard,Dominique Berton-Rigaud,Nicole Tubiana-Mathieu +71 more
TL;DR: The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial cancer and did a post-hoc survival analysis to investigate patterns of recurrence.